About_克睿基因生物科技有限公司

Introduction

Founded in Suzhou in 2016, Cure Genetics is a biotechnology company developing cutting-edge gene and cell therapies using its proprietary research platforms that includes gene editing, viral vector delivery, and molecular reconstruction. We apply these advanced technology platforms to promote the development of innovative cancer and genetic diseases therapies in order to satisfy unmet medical needs.

History

2016

July: Founded in Suzhou

2017

January: Completed Seed Round Funding: RMB 15 Million

2018

March: Series A+ $12.5 Million

December: Partnership with BI

2020

March: Series A+ $12.5 million

2021

January: Partnership with BI

July: Transition from Technology Research to Pipeline Company

November: Spinned off Diagnosis Business, GeneVide

December: Series B Funding $60 Million

2022

January: 8500㎡ Development Center in construction

2016

2017

2018

2020

2021

2022

Honor

China‘s Most Valuable Investme...

China Potential Unicorns

China's Top CAR-T Enterprises

TOP5 VB100 | Gene Editing TOP...

Jiangsu Potential Unicorns

Jiangsu Private Science & Tech...

Jiangsu Small and Medium-sized...

Team

Yuanyuan XuPhD

Founder, Chairman

Dr. Xu is a founder and Chairman of Cure Genetics. He received his Ph.D. in Biology from Tsinghua University and completed postdoctoral research at Yale University, focusing on structural and functional studies of proteins related to DNA damage, repair and tumorigenesis. Dr. Xu also has rich experience in research and development of new therapies for genetic diseases and cancers. Before founding Cure Genetics, he was Vice President of Biopharmaceutical R&D at Yabao Pharmaceutical Co., Ltd.. He is also an adjunct Professor at Soochow University.

Patrick LiuMD, PhD

Co-Founder, President

Yanni LinPhD

Co-Founder, Chief Scientist

Patrick LiuMD, PhD

Co-Founder, President

Dr. Liu is co-founder and president of Cure Genetics. He received his M.D. & Ph.D. from Peking Union Medical College. He has over 20 years’ experience of novel biological drug R&D in bio-pharma industry. Prior to Cure Genetics, Dr. Li has previously served as CSO at Livzon Pharmaceuticals, VP & CSO at Hengrui Medicine Groups, VP at Teva Pharm., and R&D director in Roche/Genentech and Tanox. Dr. Liu is one of the early scientists to apply monoclonal antibody technology in research and development of biologic drugs. Dr. Liu has led more than 100 biological projects and promoted successful approval of 12 biological drugs. He also successfully established a number of innovative drug technology platforms, including gene vector and cell therapy technology. He is also an adjunct Professor at Maryland University.

Yanni LinPhD

Co-Founder, Chief Scientist

Dr. Lin is co-founder and chief scientist of Cure Genetics. She received her Ph.D. in biomedical engineering from Georgia Institute of Technology/Emory University and B.Sc. in biological science and technology from Tsinghua University. She has over 10 years of experience in genetic modification and translational experiences using TALENs and CRISPR/Cas9 tools in mammalian systems. Dr. Lin previously served as research scientist in Synthetic Genomics and is one of inventors of TALENTM. She is an adjunct Professor at Soochow University.

SAB

Robert RuffoloPhD

In April 2022, Dr. Robert R. Ruffolo joined Cure Genetics's Scientific Advisory Board (SAB), where he will provide scientific guidance on our technology platform and R&D pipeline, collaborating to drive the internationalization of innovative products.

Dr. Ruffolo was formerly president and senior vice president (SVP) of R&D at Wyeth (now Pfizer), where he managed R&D team of over 9,000 scientists with an annual budget of $3 billion. Prior to Wyeth, he was SVP of R&D at SmithKline Beecham Pharmaceuticals (now GSK),. Dr. Ruffolo was instrumental in the discovery and development of many successful products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan, which also earned him several prestigious awards, including the 2008 PhRMA Award for Discovery.